Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lineage Cell Therapeutics Inc. Director's Dealing 2012

Jul 31, 2012

6895_dirs_2012-07-31_93b30409-bb95-49c9-88b3-b867473a761c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-07-30

Reporting Person: KINGSLEY ALFRED D (Director, See Remarks, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-30 Common Shares, no par value J 140000 $4.7661 Disposed 7512394 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Shares, no par value 1968505 Indirect
Common Shares, no par value 490373 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option to Puchase Common Shares $4.60 2017-06-30 Common Shares (50000) 50000 Direct
Option to Puchase Common Shares $5.13 2016-06-30 Common Shares (50000) 50000 Direct
Option to Puchase Common Shares $5.45 2015-08-09 Common Shares (50000) 50000 Direct
Option to Puchase Common Shares $2.30 2014-07-01 Common Shares (50000) 50000 Direct

Footnotes

F1: On July 30, 2012, Mr. Kingsley transferred 140,000 BioTime common shares to BioTime's subsidiary LifeMap, Inc. in exchange for shares of LifeMap common stock under the terms of a Share Exchange and Contribution Agreement (the "LifeMap Agreement").

F2: Price determined under the LifeMap Agreement as the highest volume weighted average closing price per share on the NYSE MKT for ten consecutive trading days during the period from July 1, 2012 through July 31, 2012.

F3: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.

F4: 12,500 options will become exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013 based upon continued service on the board of directors.

F5: 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

F6: 12,500 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.

F7: 12,500 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.